Efek Obat Antituberkulosis Fase Intensif dan Konsumsi Purin Terhadap Kadar Asam Urat Pasien Tuberkulosis

Mustaming Mustaming




A high prevalence of TB requires serious treatment with Anti-Tuberculosis Therapy, but the side effects can gain uric acid levels. This study aimed to analyze the effects of intensive phase therapy and high purine consumption patterns with uric acid levels in TB patients with Anti-Tuberculosis Therapy. This research was an analytic study using a prospective cohort design. The population was all tuberculosis patients who received Anti-Tuberculosis Therapy at several Public Health Centers in Samarinda. The sampling technique used consecutive sampling approach. The respondents were selected according to the inclusion criteria and had signed the informed consent. Furthermore, the venous blood was measured to know the levels of the uric acid pre-test. The measurements of uric acid levels post-test were carried out after undergoing Anti-Tuberculosis Therapy for 2 months and filling out the FFQ questionnaire to determine the patterns of high purine consumption. The collected data was analyzed using a t-paired and a one-way anova test. T-Paired test results exhibited that there were increasing trend in the average uric acid levels after following Anti-Tuberculosis Therapy in an intensive phase of 2.53 mg / dL (39.78%) with p-value <0.001. Besides, the one way anova test results showed that the average difference in uric acid levels in respondents who consumed high purine 4-6 times/week was 3.16 mg / dL and was higher than respondents who never consumed high purine or those who consumed high purine 1-3 times/week with a p-value <0.001. An average increase in uric acid levels in TB patients after undergoing the intensive phase of Anti-Tuberculosis Therapy for 2 months with a pyrazinamide and ethambutol regimen and an increase in uric acid levels was higher compared to respondents who consumed high purine.


Keywords: uric acid level, high purine consumption, intensive phase

Teks Lengkap:



Departemen Kesehatan, R. (2011). Pedoman nasional pengendalian tuberkulosis. Jurnal Kesehatan Masyarakat, 2011. https://doi.org/614.542 Ind p

Diana, & Matheos, J. (2013). Pengaruh Obat Antituberkulosis-Kombinasi Dosis Tetap Terhadap Kadar Asam Urat pada Pasien Tuberkulosis Paru. 40(6), 91–94.

Diantari, E., & Kusumastuti, A. C. (2013). Pengaruh Asupan Purin Dan Cairan Terhadap Kadar Asam Urat Wanita Usia 50-60 Tahun Di Kecamatan Gajah Mungkur, Semarang. Journal of Nutrition College, 2(1), 44–49. https://ejournal3.undip.ac.id/index.php/jnc/article/view/2095

Gerdan, V., Akkoc, N., Ucan, E. S., & Bulac Kir, S. (2013). Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia. Singapore Medical Journal, 54(6), 125–126. https://doi.org/10.11622/smedj.2013097

Gülbay, B. E., Gürkan, Ö. U., Yildiz, Ö. A., Önen, Z. P., Erkekol, F. Ö., Baççioǧlu, A., & Acican, T. (2006). Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine, 100(10), 1834–1842. https://doi.org/10.1016/j.rmed.2006.01.014

Haqiqi, R. N., & Wahyunita, S. (2017). Kadar Asam Urat pada Pasien Tuberkulosis dengan Terapi Obat Antituberkulosis ( OAT ) di Puskesmas Cempaka. 3(2), 173–177.

Ichida, K., Hosoyamada, M., Hisatome, I., Enomoto, A., Hikita, M., Endou, H., & Hosoya, T. (2004). Clinical and Molecular Analysis of Patients with Renal Hypouricemia in Japan-Influence of URAT1 Gene on Urinary Urate Excretion. Journal of the American Society of Nephrology, 15(1), 164–173. https://doi.org/10.1097/01.ASN.0000105320.04395.D0

Kemenkes. (2018). Tuberkulosis - InfoDATIN 2018. https://doi.org/2442-7659

Kemenkes. (2014). Profil Kesehatan Tahun. In Kementerian Kesehatan Republik Indonesia (Vol. 51, Issue 6). https://doi.org/10.1159/000324200

Kementerian Kesehatan Republik Indonesia Ditjen P2PL. (2014). Pedoman Nasional Pengendalian Tuberkulosis (p. 38).

Louthrenoo, W., Hongsongkiat, S., Kasitanon, N., Wangkaew, S., & Jatuworapruk, K. (2015). Effect of antituberculous drugs on serum uric acid and urine uric acid excretion. Journal of Clinical Rheumatology, 21(7), 346–348. https://doi.org/10.1097/RHU.0000000000000297

Mustaming, M., Loriana, R., Azhari, A., & Badar, B. (2018). Improvement of family caregivers’ knowledge of polypharmacy in the elderly after health education. Pharmaciana, 8(1), 71. https://doi.org/10.12928/pharmaciana.v8i1.7944

Nahar, B. L., Hossain, A. M., Islam, M. M., & Saha, D. R. (2006). A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh Journal of Pharmacology, 1(2), 51–57. https://doi.org/10.3329/bjp.v1i2.488

Pan, X., Wang, L., Gründemann, D., & Sweet, D. H. (2013). Interaction of ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy. Antimicrobial Agents and Chemotherapy, 57(10), 5053–5059. https://doi.org/10.1128/AAC.01255-13

Q., A., Doan, A., & Andersen, M. (2014). Pyrazinamide-induced hyperuricemia. P and T, 39(10), 695–715.

Şişmanlar, T., Aslan, A. T., & Budakoğlu, I. (2015). Is Hyperuricemia overlooked when treating pediatric tuberculosis patients with pyrazinamide? Journal of Tropical Pediatrics, 61(5), 351–356. https://doi.org/10.1093/tropej/fmv042

Villegas, R., Xiang, Y. B., Elasy, T., Xu, W. H., Cai, H., Cai, Q., Linton, M. F., Fazio, S., Zheng, W., & Shu, X. O. (2012). Purine-rich foods, protein intake, and the prevalence of hyperuricemia: The Shanghai Men’s Health Study. Nutrition, Metabolism and Cardiovascular Diseases, 22(5), 409–416. https://doi.org/10.1016/j.numecd.2010.07.012

World Health Organization. (2018). Global 2018 TB report. In WHO report (Vol. 69, Issue 4). https://doi.org/10.1016/j.pharep.2017.02.021

DOI: http://dx.doi.org/10.30651/jmlt.v5i1.7939


  • Saat ini tidak ada refbacks.